银华中证创新药产业ETF(159992)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
1,454,227,375.56 |
-1,455,291,124.38 |
-2,217,419,230.95 |
-1,120,370,598.67 |
| 利息合计 |
557,845.93 |
1,152,588.39 |
670,907.62 |
3,425,738.79 |
| 其中：存款利息收入 |
557,845.93 |
943,911.02 |
462,230.25 |
975,290.16 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
152,134,408.44 |
-1,438,936,603.94 |
-992,425,428.53 |
-833,701,076.04 |
| 其中：股票投资收益 |
69,136,905.21 |
-1,545,517,906.08 |
-1,051,375,020.71 |
-914,137,757.44 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
82,997,503.23 |
106,581,302.14 |
58,949,592.18 |
80,436,681.40 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
1,296,003,926.80 |
-39,539,371.55 |
-1,239,092,324.52 |
-297,383,570.43 |
| 其他收入 |
5,531,194.39 |
22,032,262.72 |
13,427,614.48 |
7,288,309.01 |
| 费用 |
29,771,177.02 |
43,803,849.38 |
19,769,590.93 |
43,109,847.74 |
| 管理人报酬 |
26,349,729.84 |
37,583,877.20 |
16,928,138.80 |
36,926,894.72 |
| 基金托管费 |
2,634,972.98 |
3,758,387.71 |
1,692,813.86 |
3,692,689.55 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
786,474.20 |
2,460,833.19 |
1,147,886.99 |
2,481,441.80 |
| 利润总额 |
1,424,456,198.54 |
-1,499,094,973.76 |
-2,237,188,821.88 |
-1,163,480,446.41 |
微信公众号
证券之星APP
基本资料
